Topics
- Using PKPD Modellingto Evaluate Novel Biologic Constructs
- Impact of Brentuximab Vedotin in the Treatmentof Lymphoma
- Considerations in the Development of Antibody-Maytansinoid Conjugates
- Quality Attributes That May Impact PK or Mechanism of Action
- Modeling & Simulation of Bispecific Antibodies in Oncology
- Properties of Fleximer™ to Improve Pharmacokinetics
- PK/PD Modeling to Determine Individual Dose Response
- Guiding ADC Development by Employing PK/PD Modeling and Simulation Approaches
- Engineering of pH-Dependent Binding Antibodies for Improved Pharmacokinetics
- PK Optimization of Bispecific DART Proteins for Clinical Use
- Antigen Sweeping Effect of Antibody with pH-Dependent Antigen Binding and Increased FcR Binding
Who should Attend
Senior executives and scientists from laboratories, Bio-research Centers, Pharmaceutical companies, universities, government and more.
